

Specimen Collected: 17-Dec-21 10:25**Neuronal Nuclear Abs IgG, IB, CSF** | Received: 17-Dec-21 10:25 Report/Verified: 17-Dec-21 10:27

Procedure	Result	Units	Reference Interval
Neuronal Nuclear Ab (Hu) IgG, IB, CSF	Negative ⁱ¹		Negative
Neuronal Nuclear Ab (Ri) IgG, IB, CSF	Negative ⁱ²		Negative
Neuronal Nuclear Ab (Yo) IgG, IB, CSF	Positive * ⁱ³		Negative
Neuronal Nuclear Ab (TR/DNER) IgG, CSF	Negative ⁱ⁴		Negative

Paraneoplastic Abs w/Rflx, CSF | Received: 17-Dec-21 10:25 Report/Verified: 17-Dec-21 10:27

Procedure	Result	Units	Reference Interval
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF	PCCA Detected * ^{f1 i5}		None Detected

Purkinje Cell Antibody Titer, CSF | Received: 17-Dec-21 10:25 Report/Verified: 17-Dec-21 10:27

Procedure	Result	Units	Reference Interval
Purkinje Cell Antibody Titer IgG, CSF	1:20 * ⁱ⁶		< 1:1

Result Footnote

f1: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

Test Information

i1: Neuronal Nuclear Ab (Hu) IgG, IB, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Hu)
IgG, IB, CSF

This test detects IgG antineuronal antibodies to Hu, Ri, and Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

* = Abnormal, # = Corrected, C = Critical, f = Result Footnote, H = High, i = Test Information, L = Low, t = Interpretive Text, @ = Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 21-351-900054**Report Request ID:** 15066650**Printed:** 17-Dec-21 11:37

Page 1 of 2

Test Information

i2: Neuronal Nuclear Ab (Ri) IgG, IB, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: Neuronal Nuclear Ab (Yo) IgG, IB, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: Neuronal Nuclear Ab (TR/DNER) IgG, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (TR/DNER) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

INTERPRETIVE INFORMATION: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i6: Purkinje Cell Antibody Titer IgG, CSF

INTERPRETIVE INFORMATION: Purkinje Cell Antibody Titer IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 21-351-900054

Report Request ID: 15066650

Printed: 17-Dec-21 11:37